Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Shares Outstanding (Weighted Average) (2018 - 2025)

Neurogene's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $21.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 21.4% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $21.3 million, up 21.4%, while the annual FY2025 figure was $21.3 million, 21.4% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $21.3 million in Q4 2025 per NGNE's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $21.3 million in Q4 2025 to a low of $433623.0 in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $7.2 million, with a median of $4.0 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 3471.51% in 2024, then rose 21.4% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $491867.0 in 2023, then skyrocketed by 3471.51% to $17.6 million in 2024, then rose by 21.4% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Shares Outstanding (Weighted Average) are $21.3 million (Q4 2025), $6.8 million (Q3 2025), and $21.0 million (Q2 2025).